title: Bevacizumab in the treatment of metastatic breast cancer: three case reports.
abstract: Case reports are presented for three patients with metastatic breast cancer who received first-line treatment with bevacizumab in combination with taxanes in clinical trials. Two patients showed peak reductions in lesion size of 49 and 70%, respectively. In one patient, subsequent treatment with bevacizumab in combination with capecitabine [Xeloda (after discontinuation of paclitaxel due to asthenia)] yielded peak reductions in target lesion size of 78%. One patient experienced a progression-free survival time of 16 months. In all three patients, bevacizumab was well tolerated and mostly displayed only mild toxicities.
authors.affiliation: Hospital Distrital de Santarém, Avenida Bernardo Santereno, 2000 Santarém, Portugal.
authors.forename: Ana
authors.initials: A
authors.lastname: Ferreira
authors.forename: Cláudia
authors.initials: C
authors.lastname: Vieira
authors.forename: Ana
authors.initials: A
authors.lastname: Rodrigues
authors.forename: Deolinda
authors.initials: D
authors.lastname: Pereira
authors.forename: Helena
authors.initials: H
authors.lastname: Rodrigues
authors.forename: Cristina
authors.initials: C
authors.lastname: Dávila
authors.forename: Sandra
authors.initials: S
authors.lastname: Bento
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D000068258:Bevacizumab; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D000069287:Capecitabine; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D044584:Carcinoma, Ductal / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D007680:Kidney Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D008113:Liver Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D008175:Lung Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D008207:Lymphatic Metastasis; D017239:Paclitaxel / Q000009:adverse effects; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D042461:Vascular Endothelial Growth Factor A; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D017239:Paclitaxel; D005472:Fluorouracil